Fludarabine therapy in macroglobulinemic lymphoma.

Abstract

Fludarabine, a fluorinated analogue of adenine, was given to 11 patients with macroglobulinemic lymphoma, all but one having failed prior standard chemotherapy. Five patients (45%) responded with more than a 50% reduction of immunoglobulin M (IgM) tumor mass for a projected median duration of longer than 1 year. The onset of remission was usually slow, with a median tumor halving time of 5.2 months in responding patients, emphasizing the importance of repeated courses of treatment. Fludarabine is an important new agent effective against macroglobulinemic lymphoma, and should be evaluated further in combination with other active modalities.

• Authors: H M Kantarjian, R Alexanian, C A Koller, R Kurzrock, M J Keating
• Journal: Blood (Blood) Vol. 75 Issue 10 Pg. 1928-31 (May 15 1990) ISSN: 0006-4971 [Print] United States
• PMID: 1692487 (Publication Type: Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Arabinonucleotides
• Macroglobulins
• Vidarabine Phosphate
• fludarabine phosphate

Topics

• Adult
• Aged
• Antimetabolites, Antineoplastic (administration & dosage, therapeutic use, toxicity)
• Arabinonucleotides (therapeutic use)
• Female
• Humans
• Infusions, Intravenous
• Lymphoma (blood, drug therapy)
• Macroglobulins (metabolism)
• Male
• Middle Aged
• Vidarabine Phosphate (administration & dosage, analogs & derivatives, therapeutic use, toxicity)
• Waldenstrom Macroglobulinemia (blood, drug therapy)